A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
An appropriate cell source is essential for the clinical application of bioartificial liver (BAL) system. This study aimed to test a reversibly immortalized human hepatocyte line (HepLi-4) in our newly validated choanoid fluidized bed bioreactor based BAL in pigs with fulminant hepatic failure (FHF). 15 FHF pigs were allocated to three groups: a BAL group receiving BAL treatment with HepLi-4 cells; a sham BAL group receiving cell-free BAL treatment; and a FHF group receiving intensive caredoi:10.5897/ajb11.3411 fatcat:tzktzgay55h4pcsjw4w5o56ooq